Class effects of SGLT2 inhibitors on cardiorenal outcomes

Class effects of SGLT2 inhibitors on cardiorenal outcomes

Abstract Background To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabe...

Full description

Bibliographic Details
Main Authors: Aaron Y. Kluger, Kristen M. Tecson, Andy Y. Lee, Edgar V. Lerma, Janani Rangaswami, Norman E. Lepor, Michael E. Cobble, Peter A. McCullough
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitor
Empagliflozin
Canagliflozin
Dapagliflozin
CANVAS
EMPA–REG OUTCOME
Online Access:http://link.springer.com/article/10.1186/s12933-019-0903-4

Internet

http://link.springer.com/article/10.1186/s12933-019-0903-4

Similar Items